header logo image


Page 1,298«..1020..1,2971,2981,2991,300..1,3101,320..»

‘Bebot’ Villar: Stem cell therapy made me weaker – Video

June 30th, 2013 8:43 am


#39;Bebot #39; Villar: Stem cell therapy made me weaker
MANILA, Philippines - A government official on Thursday said he is no believer in stem cell therapy after undergoing the procedure but getting zero health be...

By: TheABSCBNNews

The rest is here:
'Bebot' Villar: Stem cell therapy made me weaker - Video

Read More...

FDA urges hotels to guard vs stem cell therapy

June 30th, 2013 8:43 am

By: Jet Villa, InterAksyon.com June 29, 2013 6:55 PM

A scientist working on stem cells in a laboratory. AGENCE FRANCE-PRESSE

InterAksyon.com The online news portal of TV5

MANILA, Philippines -- The Food and Drug Administration has asked hotels to guard against allowing stem cell therapy to be performed in their premises.

FDA acting director Dr. Kenneth Hartigan-Go said hotels may be held liable for guests found performing or undergoing stem cell therapy in their rooms.

Go pointed out that performing medical procedures like stem cell therapy in a non-health facility is illegal.

Under Republic Act 9711 or the Food and Drug Administration Act of 2009, violators face a fine of up to P500,000 plus closure of the establishment and jail terms.

In FDA Advisory 2013-012 issued May 15, the agency warned the pubic against "receiving unapproved stem cell preparations in non-health facilities."

"Patients who might receive stem cell preparations and therapy without prior FDA-Department of Health approval run the risks of contracting infectious diseases and severe complications which may lead to permanent disabilities, physical deformities, serious iatrogenic harm, autoimmune diseases and worst death, and without the benefit of health insurance coverage," the advisory said.

See the rest here:
FDA urges hotels to guard vs stem cell therapy

Read More...

Gov’t to tighten rules on stem cell therapy

June 30th, 2013 8:43 am

By Michael Lim Ubac Philippine Daily Inquirer

Hospitals offering stem cell therapy have until Aug. 31 to seek or renew their accreditation from the Department of Health (DOH), a Palace official said Friday.

For the information of the public, the DOH is accrediting hospitals for this kind of treatment, and come Aug. 31, these hospitals should file their accreditation requirements (with DOH) for them to continue to offer this treatment, said deputy presidential spokesperson Abigail Valte.

The government is eyeing stricter regulation of hospitals offering stem cell therapy amid speculations that the recent deaths of three politicians were due to the xenogenic (animal-based stem cell) treatment they had received in Germany last year.

Dr. Leo Olarte, president of the Philippine Medical Association (PMA) and spokesperson of the Philippine Society for Stem Cell Medicine, said the groups were still trying to determine whether the politicians had died due to their illness or due to hypersensitivity reaction from the xenogenic stem cells.

Last week, the PMA also warned of a possible scam involving German doctors coming over to perform stem cell therapy on patients in five-star hotels at around P1 million per shot.

Valte echoed a similar warning from the DOH against doctors offering the procedure in their clinics, saying that hospitals, not (individual) doctors, nor stand-alone clinics, are the ones being accredited.

Not a cure all

The Palace official also cautioned the public against claims that stem cell therapy was a cure all (for diseases).

There is no treatment that will cure all of your ills. Much less your love problems, Valte said.

Excerpt from:
Gov’t to tighten rules on stem cell therapy

Read More...

Cost of a Stem Cell Therapy? An Estimated $512,000

June 30th, 2013 3:03 am
The likely costs of potential stem cell therapies
and cures receive almost no attention in the media as well as
publicly from scientists and the biotech firms.
Usually any public discussion is
obliquely framed in the context of “reimbursement,” as if
industry is owed something instead of making a business decision
about what will make a profit. Euphemisms and jargon cloak unpleasant realities such as astronomical patient costs. But what reimbursement really involves are, in fact, pricing decisions and profit margins along with
lobbying campaigns for inclusion of
therapies in normal coverage of health insurance and Medicare
And today a singular figure – $512,000
for one stem cell treatment – appeared in the Wall Street
Journal
. The story by Kosaku Narioka and Phred Dvorak dealt
with what would be the first-ever human study of a treatment that
uses reprogrammed adult stem cells.
They reported that the study received
preliminary approval on Wednesday from a key panel of the Japan
Health Ministry.
The treatment involves a form of age-related macular
degeneration, which has also been targeted by the California stem
cell agency with different approaches.
Buried deep in the Wall Street Journal
article, with little other discussion, was this sentence:

“One eventual obstacle, even if tests
go well, could be cost: (Masayuki) Yamato (of Tokyo Women's Medical
University
) says initial estimates for the treatment run around ¥50
million ($512,000) per person."

The subject of costs for potential stem
cell treatments has rattled around in the background for years
without much deep public discussion. One reason is that high costs of
treatments are controversial and can trigger emotional debate.
Another reason is that it is very early in the therapy development
process and estimates are not likely to be entirely reliable.
A few years ago, however, the California stem
cell agency commissioned a study involving costs of stem cell therapies. The UC Berkeley report said,

“The cost impact of the therapy is
likely to be high, because of a therapy’s high cost per patient,
and the potentially large number of individuals who might benefit
from the therapy. This expense would put additional stress on
the Medicare and Medicaid budgets, cause private
insurance health premiums to increase, and create an incentive for
private plans to avoid covering individuals eligible for a therapy.”

The findings did not seem to be exactly
welcomed. The agency sat on the 2009 study for seven months until it
was uncovered by the California Stem Cell Report in April 2010. Then
the agency was careful to say that the study did not reflect the view
of CIRM management or board leadership.
Their wariness of being out in front on the issue could be well-advised. The pharmaceutical industry received some unpleasant attention this spring when more than 100 influential cancer specialists from more than 15 countries publicly denounced the cost of cancer drugs that exceed more than $100,000 a year.
Nonetheless pricing is critical
to both patient accessibility and therapy development. If companies
cannot make a profit on a possible therapy, it is virtually certain
not to appear in the marketplace.
While the subject remains in the
background, it does not mean there is a lack of interest. The copy of
the Berkeley stem cell cost study that was posted online by the California
Stem Cell Report has been read 11,701 times since it was made
available in April 2010 on scribd.com.
A copy of the study can be found below.

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/IObtHBtAe_E/cost-of-stem-cell-therapy-estimated.html

Read More...

Bluebird and Banking: Media Pluses for California Stem Cell Agency

June 30th, 2013 3:02 am
The California stem cell agency scored
a couple of favorable publicity points last week as the result of a
successful stock offering by an award recipient and another piece
about creation of a stem cell bank in Northern California.
The IPO by bluebird bio (the company's
preferred spelling) of Massachusetts was a big winner for the
company, raising millions of dollars more than anticipated.
The Boston Globe wrote,

“Shares of the Cambridge life
sciences company bluebird bio Inc. soared almost 60 percent on their
first day of trading (last) Wednesday, an impressive debut for a
business that endured years of stagnation and another encouraging
sign for the biotechnology industry.

“The local gene therapy company
raised $101 million in an initial public offering priced at $17 per
share, higher than the $14 to $16 estimated by investment bankers.
Bluebird shares closed at $26.91 per share on Wednesday.”

The stock continues to trade around $25
a share at the time of this writing, which is good news generally for
the biotech industry.
The company received a $9.4 million
award last fall from the $3 billion stem cell agency. The company has yet to receive any actual cash from the agency as both parties work
out final details of an agreement, a spokesman for the agency said
last week.
The stem cell agency touted the
successful IPO in a blog item by  that said,

“Bluebird Bio, one of the oldest
companies in the struggling gene therapy field, is having an
outstanding first day in the stock market today, and largely by
marrying its gene therapy technology with stem cell science. The
company’s financial milestone brings hope and excitement to both
fields.”

However, the news stories about the IPO
failed to mention the stem cell agency's involvement, which would
have been nice for the agency but was to be expected given the way
news is covered.
The story about the stem cell bank
appeared on Xconomy, an Internet news service dealing with
technology. Written by Bernadette Tansey, a former San Francisco
Chronicle
reporter, the piece dealt with the both business and science of stem cell banking. She wrote,

“One of the main goals of
California’s $3 billion stem cell research agency is to draw
companies into the state so they can vie for a share of the funding.

"With a recently funded $32 million
initiative, the California
Institute for Regenerative Medicine
(CIRM) has attracted two of
the biggest US players in stem cell banking to Novato, CA, to form
one of the largest biobanks of induced pluripotent stem cells (iPS
cells) in the world.”

The stem cell bank effort has become a
minor staple in recent news coverage of CIRM, surfacing in a number
of articles since the awards were approved. One of the reasons for that is that the project has a relatively straight-forward story line compared to many research efforts and the concept of "banking" is familiar to editors, writers and readers. 

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/6WeU6kIIs6E/bluebird-and-banking-media-pluses-for.html

Read More...

Bluebird and Banking: Media Pluses for California Stem Cell Agency

June 30th, 2013 2:59 am
The California stem cell agency scored
a couple of favorable publicity points last week as the result of a
successful stock offering by an award recipient and another piece
about creation of a stem cell bank in Northern California.
The IPO by bluebird bio (the company's
preferred spelling) of Massachusetts was a big winner for the
company, raising millions of dollars more than anticipated.
The Boston Globe wrote,

“Shares of the Cambridge life
sciences company bluebird bio Inc. soared almost 60 percent on their
first day of trading (last) Wednesday, an impressive debut for a
business that endured years of stagnation and another encouraging
sign for the biotechnology industry.

“The local gene therapy company
raised $101 million in an initial public offering priced at $17 per
share, higher than the $14 to $16 estimated by investment bankers.
Bluebird shares closed at $26.91 per share on Wednesday.”

The stock continues to trade around $25
a share at the time of this writing, which is good news generally for
the biotech industry.
The company received a $9.4 million
award last fall from the $3 billion stem cell agency. The company has yet to receive any actual cash from the agency as both parties work
out final details of an agreement, a spokesman for the agency said
last week.
The stem cell agency touted the
successful IPO in a blog item by  that said,

“Bluebird Bio, one of the oldest
companies in the struggling gene therapy field, is having an
outstanding first day in the stock market today, and largely by
marrying its gene therapy technology with stem cell science. The
company’s financial milestone brings hope and excitement to both
fields.”

However, the news stories about the IPO
failed to mention the stem cell agency's involvement, which would
have been nice for the agency but was to be expected given the way
news is covered.
The story about the stem cell bank
appeared on Xconomy, an Internet news service dealing with
technology. Written by Bernadette Tansey, a former San Francisco
Chronicle
reporter, the piece dealt with the both business and science of stem cell banking. She wrote,

“One of the main goals of
California’s $3 billion stem cell research agency is to draw
companies into the state so they can vie for a share of the funding.

"With a recently funded $32 million
initiative, the California
Institute for Regenerative Medicine
(CIRM) has attracted two of
the biggest US players in stem cell banking to Novato, CA, to form
one of the largest biobanks of induced pluripotent stem cells (iPS
cells) in the world.”

The stem cell bank effort has become a
minor staple in recent news coverage of CIRM, surfacing in a number
of articles since the awards were approved. One of the reasons for that is that the project has a relatively straight-forward story line compared to many research efforts and the concept of "banking" is familiar to editors, writers and readers. 

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/6WeU6kIIs6E/bluebird-and-banking-media-pluses-for.html

Read More...

Cost of a Stem Cell Therapy? An Estimated $512,000

June 30th, 2013 2:59 am
The likely costs of potential stem cell therapies
and cures receive almost no attention in the media as well as
publicly from scientists and the biotech firms.
Usually any public discussion is
obliquely framed in the context of “reimbursement,” as if
industry is owed something instead of making a business decision
about what will make a profit. Euphemisms and jargon cloak unpleasant realities such as astronomical patient costs. But what reimbursement really involves are, in fact, pricing decisions and profit margins along with
lobbying campaigns for inclusion of
therapies in normal coverage of health insurance and Medicare
And today a singular figure – $512,000
for one stem cell treatment – appeared in the Wall Street
Journal
. The story by Kosaku Narioka and Phred Dvorak dealt
with what would be the first-ever human study of a treatment that
uses reprogrammed adult stem cells.
They reported that the study received
preliminary approval on Wednesday from a key panel of the Japan
Health Ministry.
The treatment involves a form of age-related macular
degeneration, which has also been targeted by the California stem
cell agency with different approaches.
Buried deep in the Wall Street Journal
article, with little other discussion, was this sentence:

“One eventual obstacle, even if tests
go well, could be cost: (Masayuki) Yamato (of Tokyo Women's Medical
University
) says initial estimates for the treatment run around ¥50
million ($512,000) per person."

The subject of costs for potential stem
cell treatments has rattled around in the background for years
without much deep public discussion. One reason is that high costs of
treatments are controversial and can trigger emotional debate.
Another reason is that it is very early in the therapy development
process and estimates are not likely to be entirely reliable.
A few years ago, however, the California stem
cell agency commissioned a study involving costs of stem cell therapies. The UC Berkeley report said,

“The cost impact of the therapy is
likely to be high, because of a therapy’s high cost per patient,
and the potentially large number of individuals who might benefit
from the therapy. This expense would put additional stress on
the Medicare and Medicaid budgets, cause private
insurance health premiums to increase, and create an incentive for
private plans to avoid covering individuals eligible for a therapy.”

The findings did not seem to be exactly
welcomed. The agency sat on the 2009 study for seven months until it
was uncovered by the California Stem Cell Report in April 2010. Then
the agency was careful to say that the study did not reflect the view
of CIRM management or board leadership.
Their wariness of being out in front on the issue could be well-advised. The pharmaceutical industry received some unpleasant attention this spring when more than 100 influential cancer specialists from more than 15 countries publicly denounced the cost of cancer drugs that exceed more than $100,000 a year.
Nonetheless pricing is critical
to both patient accessibility and therapy development. If companies
cannot make a profit on a possible therapy, it is virtually certain
not to appear in the marketplace.
While the subject remains in the
background, it does not mean there is a lack of interest. The copy of
the Berkeley stem cell cost study that was posted online by the California
Stem Cell Report has been read 11,701 times since it was made
available in April 2010 on scribd.com.
A copy of the study can be found below.

Source:
http://feedproxy.google.com/~r/blogspot/uqpFc/~3/IObtHBtAe_E/cost-of-stem-cell-therapy-estimated.html

Read More...

Stem Cell Therapy Becomes More Widely Available | Video ABC News – Video

June 28th, 2013 10:42 am


Stem Cell Therapy Becomes More Widely Available | Video ABC News
Beverly Hills Orthopedic surgeon Dr. Raj appeared on ABC #39;s Good Morning America to share the breatkthrough stem cell treatment that #39;s now available to weeken...

By: AHPRvideo

View post:
Stem Cell Therapy Becomes More Widely Available | Video ABC News - Video

Read More...

Punto por Punto: Phil Medical Association, nagbabala sa iligal na pagsasagawa ng stem cell therapy – Video

June 28th, 2013 10:42 am


Punto por Punto: Phil Medical Association, nagbabala sa iligal na pagsasagawa ng stem cell therapy
MANILA - Punto por Punto host Anthony Taberna discusses the possible dangers of illegal stem cell therapy.

By: TheABSCBNNews

Go here to see the original:
Punto por Punto: Phil Medical Association, nagbabala sa iligal na pagsasagawa ng stem cell therapy - Video

Read More...

63 year old stroke victim was greatly improved through stem cell therapy – Video

June 28th, 2013 10:42 am


63 year old stroke victim was greatly improved through stem cell therapy

By: Gökhan Akdo #287;an

Visit link:
63 year old stroke victim was greatly improved through stem cell therapy - Video

Read More...

Foreign doctors behind illegal stem cell therapy – Video

June 28th, 2013 10:42 am


Foreign doctors behind illegal stem cell therapy
The Philippine Medical Association wants to go after foreign doctors who are reportedly conducting unauthorized stem cell procedures in the country.

By: TheABSCBNNews

Excerpt from:
Foreign doctors behind illegal stem cell therapy - Video

Read More...

Paralyzed German Shepard Receives Revolutionary Stem Cell Therapy! – Video

June 28th, 2013 10:42 am


Paralyzed German Shepard Receives Revolutionary Stem Cell Therapy!

By: Stemlogix, LLC

Continue reading here:
Paralyzed German Shepard Receives Revolutionary Stem Cell Therapy! - Video

Read More...

After P900K stem cell therapy, PH official feels worse

June 28th, 2013 10:42 am

MANILA - A government official on Thursday said he is no believer in stem cell therapy after undergoing the procedure but getting zero health benefits.

Speaking to radio dzMM, Dangerous Drugs Board chairman Antonio "Bebot" Villar said he was enticed to try out the procedure after hearing from other people about the near-miraculous effect of stem cell therapy.

He noted that even former President Joseph Estrada has attributed his rejuvenated health to stem cells.

"Kasi nababalitaan ko maganda itong stem cell. Ako ay madalas na [masakit] ang buto ko. Siguro nanghihina yung buto ko na at tsaka medyo mahina ang katawan ko kaya sinubukan ko ito," he said.

Villar said he paid 16,000 euros or more than P900,000 to Villamedica for stem cell therapy to cure aches and pains in his bones and general body weakness.

He said he underwent treatment with his wife at Makati Shangri-la hotel, along with at least a dozen others.

"July 9 may schedule na stem cell sa Shangri-la EDSA. Mga dose or kinse kami. Halos buong floor, yun chairman doctor kasama assistants na taga-Thailand," he said.

The DDB chief said he received several injections on the buttocks and ordered to stay in the hotel for a day so doctors could monitor their blood pressure. He said the stem cells were harvested from lambs.

He said that after the treatment, he tried to see if he got stronger but only felt worse.

"Ang lakas ng loob ko at naniniwala ako. Naglakad ako. Abay, sumakit ang mga paa ko. Parang wala itong epekto," he said.

Read the rest here:
After P900K stem cell therapy, PH official feels worse

Read More...

MaSTherCell – World Stem Cells Regenerative Medicine Congress 2013 – Video

June 28th, 2013 12:43 am


MaSTherCell - World Stem Cells Regenerative Medicine Congress 2013
We spoke with some of the sponsors at Europe #39;s largest stem cells and regenerative medicine industry conference. This is a three day congress that stages a s...

By: biopharmachannel

View original post here:
MaSTherCell - World Stem Cells Regenerative Medicine Congress 2013 - Video

Read More...

Merck Millipore – World Stem Cells Regenerative Medicine Congress 2013 – Video

June 28th, 2013 12:43 am


Merck Millipore - World Stem Cells Regenerative Medicine Congress 2013
We spoke with some of the sponsors at Europe #39;s largest stem cells and regenerative medicine industry conference. This is a three day congress that stages a s...

By: biopharmachannel

Read the original here:
Merck Millipore - World Stem Cells Regenerative Medicine Congress 2013 - Video

Read More...

Terumo BCT – World Stem Cells Regenerative Medicine Congress 2013 – Video

June 28th, 2013 12:43 am


Terumo BCT - World Stem Cells Regenerative Medicine Congress 2013
We spoke with some of the sponsors at Europe #39;s largest stem cells and regenerative medicine industry conference. This is a three day congress that stages a s...

By: biopharmachannel

See original here:
Terumo BCT - World Stem Cells Regenerative Medicine Congress 2013 - Video

Read More...

Genbiotech – World Stem Cells Regenerative Medicine Congress 2013 – Video

June 28th, 2013 12:43 am


Genbiotech - World Stem Cells Regenerative Medicine Congress 2013
We spoke with some of the sponsors at Europe #39;s largest stem cells and regenerative medicine industry conference. This is a three day congress that stages a s...

By: biopharmachannel

Read the original here:
Genbiotech - World Stem Cells Regenerative Medicine Congress 2013 - Video

Read More...

Cryoport – World Stem Cells Regenerative Medicine Congress 2013 – Video

June 28th, 2013 12:43 am


Cryoport - World Stem Cells Regenerative Medicine Congress 2013
We spoke with some of the sponsors at Europe #39;s largest stem cells and regenerative medicine industry conference. This is a three day congress that stages a s...

By: biopharmachannel

More here:
Cryoport - World Stem Cells Regenerative Medicine Congress 2013 - Video

Read More...

Quality Assistance S.A. – World Stem Cells Regenerative Medicine Congress – Video

June 28th, 2013 12:43 am


Quality Assistance S.A. - World Stem Cells Regenerative Medicine Congress
We spoke with some of the sponsors at Europe #39;s largest stem cells and regenerative medicine industry conference. This is a three day congress that stages a s...

By: biopharmachannel

Read more here:
Quality Assistance S.A. - World Stem Cells Regenerative Medicine Congress - Video

Read More...

Savsu Technologies – World Stem Cells Regenerative Medicine Congress 2013 – Video

June 28th, 2013 12:43 am


Savsu Technologies - World Stem Cells Regenerative Medicine Congress 2013
We spoke with some of the sponsors at Europe #39;s largest stem cells and regenerative medicine industry conference. This is a three day congress that stages a s...

By: biopharmachannel

Go here to read the rest:
Savsu Technologies - World Stem Cells Regenerative Medicine Congress 2013 - Video

Read More...

Page 1,298«..1020..1,2971,2981,2991,300..1,3101,320..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick